Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4994 - Trajectory of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) predicts time to progression (TTP) in metastatic colorectal cancer (mCRC) patients.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

End-of-Life Care

Tumour Site

Colon and Rectal Cancer

Presenters

Sophie A. Kurk

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

S.A. Kurk1, R.K. Stellato2, P.H.M. Peeters2, M. Oskam2, B.D. Dorresteijn3, M. Jourdan3, C.J.A. Punt4, M. Koopman5, A.M. May6

Author affiliations

  • 1 Medical Oncology, UMC - University Medical Center Utrecht, 3584 CX - Utrecht/NL
  • 2 Epidemiology, Julius Center for Health Sciences and Primary Care, Utrecht University, 3584 CX - Utrecht/NL
  • 3 Nutricia Advanced Medical Nutrition, Danone Nutricia Research, 3584 CT - Utrecht/NL
  • 4 Medical Oncology, Academic Medical Center, University of Amsterdam, 1100 DD - Amsterdam/NL
  • 5 Medical Oncology, University Hospital Utrecht, 3508 GA - Utrecht/NL
  • 6 Julius Center, University Hospital Utrecht, 3508 GA - Utrecht/NL

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4994

Background

In mCRC patients, SMI loss is suggested to be related with poor survival. Little is known on the trajectory of SMI and its relation with TTP. The CAIRO3 study (Simkens, Lancet 2015) randomized 557 mCRC patients after 6 cycles CAPOX-B to maintenance CAP-B vs. observation (obs). Upon 1st disease progression (PD1), CAPOX-B or other Tx was reintroduced until 2nd progression (PD2). Here we study if SMI trajectory predicts TTP in CAIRO3.

Methods

104 randomly selected CAIRO3 patients (mean age 65.4±8.3 years) were analyzed for SMI (skeletal muscle area at the L3 level in cm2/m2) using 9-weekly repeated CT scans (854 in total). Joint longitudinal-survival modeling, using mixed effects models for longitudinal SMI measures and Cox regression models for TTP analysis, was used to estimate hazard ratios (HR) for absolute SMI and SMI trajectory (per unit SMI loss per month) during two time periods: p1) from randomization to PD1 and p2) from PD1 to PD2. SMI trajectories were modeled throughout each time period and change was investigated at 9 and 4 weeks pre-PD.

Results

During p1 (less intensive CAP-B / obs), patients gained SMI (mean +1.1 ±3.2 cm2/m2). Absolute SMI was not related with PD1 (HR SMI 9 weeks pre-PD1 0.99 [0.96-1.02], 4 weeks pre-PD1 0.99 [0.96-1.02]). A decrease in SMI preceding PD1 showed a higher, but non-significant, risk of early PD1 (HR SMI change 9 weeks pre-PD1 1.04 [0.83-2.56], 4 weeks pre-PD1 1.53 [0.91-2.55]. During p2, (more intensive CAPOX-B / other Tx), patients lost SMI (mean -2.7 ±3.4 cm2/m2). Both SMI and SMI trajectory were significantly related to PD2 (HR SMI 9 weeks pre-PD2 1.03 [1.01-1.08], 4 weeks pre-PD2 1.04 [1.01-1.08], SMI change 9 weeks pre-PD2 1.37 [1.07-1.75], 4 weeks pre-PD2 1.23 [0.83-1.82]).

Conclusions

In mCRC patients, a decrease in SMI tended to predict shorter TTP during less intensive CAP-B or obs. SMI and SMI trajectory predicted shorter TTP during more intensive CAPOX-B or other reintroduction Tx. This large longitudinal analysis is the first to show that the trajectory of SMI loss predicts early TTP. These data suggest that SMI preservation may be a therapeutic goal.

Clinical trial identification

NCT00442637.

Legal entity responsible for the study

Anne May.

Funding

Province of Utrecht, The Netherlands and the Dutch Colorectal Cancer Group (DCCG).

Editorial Acknowledgement

Disclosure

B.D. Dorresteijn, M. Jourdan: Employee: Nutricia Research. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.